MET and non-small cell lung carcinoma: The comparison among predicted, existing, and combined results and the p values that were computed using the rank-sum test between the NSCLC group and the other group were illustrated in Figure 5. It has been reported that the PHA-665752 could act as a c-MET inhibitor to prevent K-ras mutant NSCLC60, 68 or to treat NSCLC by cooperating with rapamycin.69